VINCI CAPITAL
VC Fund
Lausanne, Switzerland
Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $10M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries VINCI CAPITAL invests in
Stages VINCI CAPITAL invests in
Countries VINCI CAPITAL invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $8.6M–$20M
- Series B
- $21M–$36M
Investment Focus
Industry
- Medical 6 (40%)
- Health Care 6 (40%)
- Biotechnology 6 (40%)
- Software 3 (20%)
- Consulting 2 (13%)
Stage
- Series A 3 (20%)
- Series B 3 (20%)
- Funding Round 3 (20%)
- Post-IPO Equity 2 (13%)
- Series C 1 (7%)
Country
- Switzerland 10 (67%)
- Germany 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christian Waldvogel
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Jean-Luc Chenaux
Chairman of the Board
|
Chairman of the Board | Total investments: 0 | Find email | |
Sabine Andre
Administrative Manager, Compliance officer
|
Administrative Manager, Compliance officer | Total investments: 0 | Find email | |
Xavier Paternot
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Claude Suard
Managing Partner
|
Managing Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
beqom
|
Happiness is the best driver for success.Their mission is to make the workforce of their customers happy. beqom drives happiness by allowing business managers to lead, align and motivate employees and partners. The beqom Total Compensation platform is used globally across all industry sectors by over 100 large companies such as Microsoft andVodafone. It addresses all Performance and Compensation aspects such as Salary Review, Bonus, Long-Term Incentives, Commissions, Benefits, Non-cash rewards and all key drivers towards Employee Performance and Sales Performance. HR, Sales and Finance organizations leverage their platform to drive performance, retention, cost optimization and... happiness among their people.beqom – to make your people happy. | $10.6M / Convertible Note / Apr 01, 2014 | |
Anergis
|
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland. | $9.3M / Series A / Feb 07, 2014 | |
SENSIMED
|
Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland. | Series C / Oct 09, 2012 | |
|
Anergis
|
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland. | $20M / Series A / Mar 28, 2011 | |
SolvAxis
|
SolvAxis is a leader in the design of ERP systems for SMEs . Since 1987, they offer enterprise software and related services. Their innovative and reliable ProConcept ERP solution lets you create and manage your business processes efficiently. 15'000 users on more than 1000 sites are already working with this standard solution. They are moreand more numerous every day.Relationships with their customers, prospects and partners are based on mutual trust. Thus, their employees give your project a great importance. They collaborate with you in a close and constructive way. | $4.6M / Feb 02, 2010 | |
Evolva
|
Evolva is a biotech company that develops and commercializes ready-to-formulate and nature-based ingredients. Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small-molecule drugs and other compounds. In particular, their platform allows the creation of chemistriesthat recapitulate the themes found in natural products, but without the disadvantages of those approaches.The company is headquartered in Reinach, Switzerland. | $27.5M / Post-IPO Equity / Dec 11, 2009 | |
|
Evolva
|
Evolva is a biotech company that develops and commercializes ready-to-formulate and nature-based ingredients. Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small-molecule drugs and other compounds. In particular, their platform allows the creation of chemistriesthat recapitulate the themes found in natural products, but without the disadvantages of those approaches.The company is headquartered in Reinach, Switzerland. | $32.6M / Series B / Oct 22, 2009 | |
Symetis
|
Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases.Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features aunique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use. | $21.3M / Series B / Jul 01, 2009 | |
Omnisens SA
|
OMNISENS was created in 1999 as a spin-off company of the Swiss Federal Institute of Technology (EPFL ). Omnisens produces instrumentation and systems based on optical metrology and photonics.Using fiber optic-based sensing Omnisens offers continuous, reliable monitoring for energy industry assets. A range of solutions is available for earlydetection and location of events which may threaten the integrity of the asset. These techniques provide condition monitoring, asset optimization and intrusion detection, based on small changes in temperature, strain and vibration. Monitoring techniques include Brillouin-based Distributed Temperature and Strain Sensing (DTSS), which Omnisens pioneered, Raman Distributed Temperature Sensing(DTS), Distributed Acoustic/Vibration Sensing (DAS/DVS) and Fiber Bragg Gratings (FBG).Based in Switzerland Omnisens operates throughout the world, either directly or through specialized solution providers, via dedicated application, commissioning and customer service teams. A leader in long-distance fiber optic sensing, Omnisens has pioneered effective real-time asset integrity monitoring solutions for critical oil and gas, power and civil engineering infrastructures. | $5.3M / Sep 10, 2008 | |
|
SENSIMED
|
Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland. | $9.3M / Series A / Dec 17, 2007 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does VINCI CAPITAL invest in?
VINCI CAPITAL invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is VINCI CAPITAL's check size?
VINCI CAPITAL typically joins rounds of $8.6M–$20M at Series A and $21M–$36M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds VINCI CAPITAL participates in.
How do I contact VINCI CAPITAL?
Public channels for VINCI CAPITAL include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at VINCI CAPITAL?
The team at VINCI CAPITAL includes Christian Waldvogel (Managing Partner), Jean-Luc Chenaux (Chairman of the Board) and Sabine Andre (Administrative Manager, Compliance officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
